Latest news

Filter by category:

FILTER: ALL CATEGORIESFilter by:

Latest news

01 Mar 2021

Going universal: The search for an all-in-one coronavirus vaccine
Instead of working to make vaccines against each unique coronavirus or variant, what if we could provide broad protection across the field through an all-in-one coronavirus shot? 

Read more

Read article

01 Mar 2021

First COVID-19 COVAX vaccine doses administered in Africa
Côte d’Ivoire and Ghana began COVID-19 vaccination campaigns aimed at protecting healthcare workers. A further 11 million COVAX doses are expected to be delivered over the next seven days.

Read more

25 Feb 2021

In the fight against novel COVID-19 variants, Norway and Germany provide vital additional funds to CEPI
The donations come at a critical time as CEPI works to advance vaccines against COVID-19 variants.

Read more

24 Feb 2021

COVID-19 vaccine doses shipped by the COVAX Facility head to Ghana, marking beginning of global rollout
600,000 doses of the AstraZeneca/Oxford vaccine licensed to Serum Institute of India have arrived in Accra, Ghana; further deliveries are expected this week.

Read more

23 Feb 2021

CEPI partner INOVIO launches Lassa vaccine Phase I trial in West Africa
It is the first vaccine clinical trial to be conducted in the region where the the disease is endemic.

Read more

18 Feb 2021

New infectious disease R&D grant opportunity launches for Canadian researchers
The joint funding opportunity, launched by CEPI and CIHR-III, will support up to six independent mid-career researchers to undertake projects on CEPI’s priority diseases, including COVID-19.

Read more

16 Feb 2021

COVAX Statement on WHO Emergency Use Listing for AstraZeneca/Oxford COVID-19 Vaccine
The announcement means that two versions of the vaccine are now available for global rollout through the COVAX Facility.

Read more

08 Feb 2021

COVAX Statement on New Variants of SARS-CoV-2
The emergence of variants of SARS-CoV-2, the virus that causes COVID-19,  serve as a powerful reminder that viruses by their very nature mutate, and that the scientific response may need to adapt if they are to remain effective against them.

Read more

Read article

03 Feb 2021

COVAX publishes first interim distribution forecast
The forecast provides interim information on early projected availability of doses in first half of 2021 to COVAX Facility participants.

Read more

01 Feb 2021

CEPI and Dynavax collaborate to secure adjuvant for COVID-19 vaccines in 2021
Agreement supports the supply of Dynavax’s CpG 1018 vaccine adjuvant in 2021 for CEPI-funded COVID-19 vaccine development programmes

Read more

01 Feb 2021

A leap forward in vaccine technology
By building on the lessons learned in 2020, it should be possible in the long term to compress vaccine development timelines still further

Read more

©2021 CEPI. All rights reserved

This website uses cookies to improve functionality and performance. If you continue browsing the site, you consent to the use of cookies on this website. For details, see our Cookie Notice.